Cybrexa Therapeutics' Series B Round

Cybrexa Therapeutics raised a round of funding on June 15, 2017.

Cybrexa Therapeutics is a biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment.…

Articles about Cybrexa Therapeutics' Series B Round: